Zahid Ahmad
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zahid Ahmad has a total of 233 co-authors. Here are the top co-authors by number of shared publications:
- Amit Khera
University of Texas Southwestern Medical Center
7 shared publications - Chao Xing
Eugene McDermott Center for Human Growth and Development, The University of Texas Southwestern Medical Center, Dallas, USA
5 shared publications Iris Kindt
The FH Foundation, Pasadena, CA, USA
5 shared publicationsAbhimanyu Garg
4 shared publicationsAmit Khera
Division of Cardiology, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA
4 shared publicationsBeverley Adams-Huet
Division of Biostatistics, Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, Texas
4 shared publications
Latest Publications
- Open Access
Projected Population-Level Impact of Digital Return of Results for Cardiovascular–Kidney–Metabolic Screening at US Blood Donation Centers: A Monte Carlo Simulation Study
Background: Cardiovascular–kidney–metabolic (CKM) syndrome affects nearly 90% of US adults, yet most individuals at early, modifiable stages remain unidentified outside clinical care. Blood donation centers offer a scalable, non-clinical venue for CKM screening, but the potential benefit of screening in this context remains unclear. We projected the population-level impact of effective digital return of results (ROR) to inform the design of a pragmatic trial. Methods: We developed a Monte Carlo simulation (100,000 iterations) of the incident major adverse cardiovascular events (MACE), end-stage renal disease (ESRD), and type 2 diabetes (T2DM) preventable by ROR-prompted, guideline-concordant follow-up among donors in CKM Stages 1–2. The estimand counts only events averted by donors who act because of ROR; the intervention effect was modeled directly on strictly positive support, and action was translated into prevented events through a hazard-based cumulative-incidence difference that counts each donor at most once. We evaluated 18 design cells (donor volumes 300,000, 1 million, and 8 million/year; 5- and 10-year horizons; action-rate gains of +10, +20, and +30 percentage points [pp]) and, in a complementary two-arm simulation, the assurance (expected power) of detecting the effect in a single deployment. Results: Under the primary +20 pp scenario, ROR at a single large blood center (300,000 donors/year) is projected to prevent a median of 2,201 events (95% uncertainty interval [UI], 1,099–4,364) over 10 years, scaling to 58,526 (29,154–116,769) at the national donor pool. All 18 design cells had strictly positive 95% lower bounds. The number needed to screen was 136 and the screening cost $2,045 per event prevented (at $15/donor), both invariant to donor volume. Impact scaled linearly with volume and effect size but sub-linearly with the horizon. Detection of the effect was effectively certain at gains of +20 pp or larger (assurance ≥99.6% in every cell and >99.9% in all but the smallest 5-year cell). Conclusions: Even under the conservative scenario, digital CKM ROR at blood donation centers is projected to prevent hundreds to tens of thousands of incident cardiometabolic events at a screening cost per event well within accepted prevention benchmarks, providing prospective, quantitative justification for a pragmatic, randomized evaluation of digital ROR in non-clinical screening settings.
Open AccessProjected Population-Level Impact of Digital Return of Results for Cardiovascular–Kidney–Metabolic Screening at US Blood Donation Centers: A Monte Carlo Simulation Study
Background: Cardiovascular–kidney–metabolic (CKM) syndrome affects nearly 90% of US adults, yet most individuals at early, modifiable stages remain unidentified outside clinical care. Blood donation centers offer a scalable, non-clinical venue for CKM screening, but the potential benefit of screening in this context remains unclear. We projected the population-level impact of effective digital return of results (ROR) to inform the design of a pragmatic trial. Methods: We developed a Monte Carlo simulation (100,000 iterations) of the incident major adverse cardiovascular events (MACE), end-stage renal disease (ESRD), and type 2 diabetes (T2DM) preventable by ROR-prompted, guideline-concordant follow-up among donors in CKM Stages 1–2. The estimand counts only events averted by donors who act because of ROR; the intervention effect was modeled directly on strictly positive support, and action was translated into prevented events through a hazard-based cumulative-incidence difference that counts each donor at most once. We evaluated 18 design cells (donor volumes 300,000, 1 million, and 8 million/year; 5- and 10-year horizons; action-rate gains of +10, +20, and +30 percentage points [pp]) and, in a complementary two-arm simulation, the assurance (expected power) of detecting the effect in a single deployment. Results: Under the primary +20 pp scenario, ROR at a single large blood center (300,000 donors/year) is projected to prevent a median of 2,201 events (95% uncertainty interval [UI], 1,099–4,364) over 10 years, scaling to 58,526 (29,154–116,769) at the national donor pool. All 18 design cells had strictly positive 95% lower bounds. The number needed to screen was 136 and the screening cost $2,045 per event prevented (at $15/donor), both invariant to donor volume. Impact scaled linearly with volume and effect size but sub-linearly with the horizon. Detection of the effect was effectively certain at gains of +20 pp or larger (assurance ≥99.6% in every cell and >99.9% in all but the smallest 5-year cell). Conclusions: Even under the conservative scenario, digital CKM ROR at blood donation centers is projected to prevent hundreds to tens of thousands of incident cardiometabolic events at a screening cost per event well within accepted prevention benchmarks, providing prospective, quantitative justification for a pragmatic, randomized evaluation of digital ROR in non-clinical screening settings.
- Open Access
Patient and Clinician Perspectives on Centralized Cascade Screening for Familial Hypercholesterolemia in the United States: A Qualitative Implementation Study
Objective: To identify patient- and clinician-reported barriers, facilitators, and design requirements for a centralized cascade-screening program for familial hypercholesterolemia (FH) in the United States. Methods: From June through November 2023, we conducted individual telephone interviews with 20 patients with FH and 10 clinicians recruited from UT Southwestern Medical Center, Parkland Health, the North Texas Veterans Affairs, and other clinical settings. Interview guides were informed by the Consolidated Framework for Implementation Research. Transcripts were coded in Dedoose using a piloted codebook, with discrepancies and emergent themes resolved through consensus. An advisory panel then helped translate interview findings into program design requirements and implementation strategies. Results: Five themes characterized barriers and facilitators to centralized cascade screening: (1) health-system access and fragmentation, including screening and treatment costs, transportation, and cross-system coordination; (2) privacy and trust, including concerns about genetic information and unsolicited outreach; (3) family relationships and practical burden, including competing demands, language barriers, limited contact, fear, and denial; (4) clinician capacity and workflow, including limited time, knowledge, and genetic-counseling capacity; and (5) communication and care continuity. Participants recommended proband pre-notification of relatives, culturally and linguistically responsive materials, secure data exchange, standardized scripts, flexible testing pathways, and centralized coordination. These findings informed a program model incorporating a secure pedigree platform, educational and communication resources, testing coordination, and linkage to follow-up care. Conclusions: Patients and clinicians identified multilevel determinants that a centralized FH cascade-screening program must address. The findings support specific design requirements but do not establish program feasibility or effectiveness, which require prospective evaluation.
Open AccessPatient and Clinician Perspectives on Centralized Cascade Screening for Familial Hypercholesterolemia in the United States: A Qualitative Implementation Study
Objective: To identify patient- and clinician-reported barriers, facilitators, and design requirements for a centralized cascade-screening program for familial hypercholesterolemia (FH) in the United States. Methods: From June through November 2023, we conducted individual telephone interviews with 20 patients with FH and 10 clinicians recruited from UT Southwestern Medical Center, Parkland Health, the North Texas Veterans Affairs, and other clinical settings. Interview guides were informed by the Consolidated Framework for Implementation Research. Transcripts were coded in Dedoose using a piloted codebook, with discrepancies and emergent themes resolved through consensus. An advisory panel then helped translate interview findings into program design requirements and implementation strategies. Results: Five themes characterized barriers and facilitators to centralized cascade screening: (1) health-system access and fragmentation, including screening and treatment costs, transportation, and cross-system coordination; (2) privacy and trust, including concerns about genetic information and unsolicited outreach; (3) family relationships and practical burden, including competing demands, language barriers, limited contact, fear, and denial; (4) clinician capacity and workflow, including limited time, knowledge, and genetic-counseling capacity; and (5) communication and care continuity. Participants recommended proband pre-notification of relatives, culturally and linguistically responsive materials, secure data exchange, standardized scripts, flexible testing pathways, and centralized coordination. These findings informed a program model incorporating a secure pedigree platform, educational and communication resources, testing coordination, and linkage to follow-up care. Conclusions: Patients and clinicians identified multilevel determinants that a centralized FH cascade-screening program must address. The findings support specific design requirements but do not establish program feasibility or effectiveness, which require prospective evaluation.
- 12 June 2026
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 20 (9) , 15-19
The return of “goals” in the 2026 ACC/AHA/Multisociety Guideline on the Management of Dyslipidemia
- 12 June 2026
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 20 (9) , 15-19
The return of “goals” in the 2026 ACC/AHA/Multisociety Guideline on the Management of Dyslipidemia
- Open Access
- 2 April 2026
- Published by Elsevier in American Journal of Preventive Cardiology
- Vol. 27, 101603
Gaps in lipid screening and statin use among uninsured patients in a charitable community clinic
- 2 April 2026
- Published by Elsevier in American Journal of Preventive Cardiology
- Vol. 27, 101603
Open AccessGaps in lipid screening and statin use among uninsured patients in a charitable community clinic
- Top Cited PapersOpen Access
- 29 January 2026
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 20 (4) , 708-737
Update on familial hypercholesterolemia: An expert clinical consensus from the National Lipid Association
- 29 January 2026
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 20 (4) , 708-737
Top Cited PapersOpen AccessUpdate on familial hypercholesterolemia: An expert clinical consensus from the National Lipid Association
- Open Access
- 25 September 2025
- Published by The Endocrine Society in JCEM Case Reports
- Vol. 3 (11) , luaf234
Sitosterolemia Due to a New Combination of ABCG8 Variants Presenting as Hemolytic Anemia and Macrothrombocytopenia
Sitosterolemia is a rare, autosomal recessive lipid disorder caused by mutations in adenosine triphosphate–binding cassette subfamily G member 5 or 8 (ABCG5/8), leading to excessive absorption and systemic accumulation of plant sterols. Patients typically present with xanthelasma, tendon xanthomas, premature atherosclerosis, and hematologic abnormalities. We report a case of sitosterolemia in a man presenting with hemolytic anemia, macrothrombocytopenia, and hypercholesterolemia. Genetic testing revealed a novel combination of ABCG8 variants, expanding the known spectrum of pathogenic mutations associated with this condition. The patient was treated with statin, ezetimibe, and low plant sterol diet, and after 9 months his plasma sterol levels improved.
- 25 September 2025
- Published by The Endocrine Society in JCEM Case Reports
- Vol. 3 (11) , luaf234
Open AccessSitosterolemia Due to a New Combination of ABCG8 Variants Presenting as Hemolytic Anemia and Macrothrombocytopenia
Sitosterolemia is a rare, autosomal recessive lipid disorder caused by mutations in adenosine triphosphate–binding cassette subfamily G member 5 or 8 (ABCG5/8), leading to excessive absorption and systemic accumulation of plant sterols. Patients typically present with xanthelasma, tendon xanthomas, premature atherosclerosis, and hematologic abnormalities. We report a case of sitosterolemia in a man presenting with hemolytic anemia, macrothrombocytopenia, and hypercholesterolemia. Genetic testing revealed a novel combination of ABCG8 variants, expanding the known spectrum of pathogenic mutations associated with this condition. The patient was treated with statin, ezetimibe, and low plant sterol diet, and after 9 months his plasma sterol levels improved.
- 2 June 2025
- Published by Elsevier in Journal of Clinical Lipidology
Lipoprotein X – Pathophysiology, diagnosis, and management
- 2 June 2025
- Published by Elsevier in Journal of Clinical Lipidology
Lipoprotein X – Pathophysiology, diagnosis, and management
- Top Cited Papers
- 22 March 2025
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 19 (3) , 382-403
Familial chylomicronemia syndrome: An expert clinical review from the National Lipid Association
- 22 March 2025
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 19 (3) , 382-403
Top Cited PapersFamilial chylomicronemia syndrome: An expert clinical review from the National Lipid Association